Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 6/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 6/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 1.00 |
| ▸ | HSPA1A | P0DMV8 | 4/20 | 1.00 |
| ▸ | HSPA8 | P11142 | 4/20 | 1.00 |
| ▸ | BRCA1 | P38398 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | CDC25A | P30304 | 1/20 | 1.00 |
| ▸ | CDC25B | P30305 | 1/20 | 1.00 |
| ▸ | STAT6 | P42226 | 1/20 | 1.00 |
| ▸ | GNG2 | P59768 | 9/20 | 0.56 |
| ▸ | GNB1 | P62873 | 9/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | GAPDH | P04406 | 1/20 | 0.56 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29986877 | 1.00 | HPGD (1.00) | HPGDALOX15HSD17B10HSPA1AHSPA8 | |
| SCHEMBL21479633 | 0.89 | ALOX15 (0.80) | HPGDALOX15HSD17B10HSPA1AHSPA8 | |
| SCHEMBL13771874 | 0.87 | HPGD (0.77) | HPGDALOX15HSD17B10HSPA1AHSPA8 | |
| SCHEMBL23386706 | 0.85 | ALOX15 (0.74) | HPGDALOX15HSD17B10HSPA1AHSPA8 | |
| SCHEMBL23386748 | 0.83 | ALOX15 (0.70) | HPGDALOX15HSD17B10HSPA1AHSPA8 | |
| SCHEMBL21479634 | 0.82 | ALOX15 (0.70) | HPGDALOX15HSD17B10HSPA1AHSPA8 | |
| SCHEMBL12051949 | 0.80 | ALOX15 (0.66) | HPGDALOX15HSD17B10HSPA1AHSPA8 | |
| SCHEMBL10911989 | 0.79 | HPGD (0.65) | HPGDALOX15HSD17B10HSPA1AHSPA8 | |
| SCHEMBL13352283 | 0.72 | GNG2 (0.71) | HPGDALOX15HSD17B10HSPA1AHSPA8 | |
| SCHEMBL2846330 | 0.72 | GNG2 (1.00) | HPGDALOX15HSD17B10HSPA1AHSPA8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306031-A1 | Methods of Inhibiting Poxvirus Growth | SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2008-12-11 | — | — | US | claimed |
| WO-2007047339-A2 | METHODS OF INHIBITING POXVIRUS GROWTH | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2007-04-26 | — | — | WO | claimed |
| US-5877210-A | CONTROLLING IMMUNE RESPONSE | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-03-02 | — | — | US | claimed |
| US-5583242-A | VANADYL COMPLEXES | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-12-10 | — | — | US | claimed |
| US-20250269043-A1 | TARGETED BIFUNCTIONAL DEGRADERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2025-08-28 | — | — | US | disclosed |
| EP-4493221-A2 | TARGETED BIFUNCTIONAL DEGRADERS | Yale University (US) | 2025-01-22 | — | — | EP | disclosed |
| WO-2023178199-A2 | TARGETED BIFUNCTIONAL DEGRADERS | YALE UNIVERSITY (US) | 2023-09-21 | — | — | WO | disclosed |
| US-20230241078-A1 | Vanadyl and vanadate for use in reducing stress-induced metabolic derangement | CFM PHARMA HOLDING B.V. (NL) | 2023-08-03 | — | — | US | disclosed |
| US-20230087994-A1 | TARGETED BIFUNCTIONAL DEGRADERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-03-23 | — | — | US | disclosed |
| CN-115315272-A | Targeting difunctional degradation agent | 耶鲁大学 | 2022-11-08 | — | — | CN | disclosed |
| EP-4041262-A1 | TARGETED BIFUNCTIONAL DEGRADERS | Yale University (US) | 2022-08-17 | — | — | EP | disclosed |
| WO-2021072269-A1 | TARGETED BIFUNCTIONAL DEGRADERS | YALE UNIVERSITY (US) | 2021-04-15 | — | — | WO | disclosed |
| US-20080306031-A1 | Methods of Inhibiting Poxvirus Growth | SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2008-12-11 | — | — | US | disclosed |
| WO-2007047339-A2 | METHODS OF INHIBITING POXVIRUS GROWTH | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2007-04-26 | — | — | WO | disclosed |
| US-5877210-A | CONTROLLING IMMUNE RESPONSE | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-03-02 | — | — | US | disclosed |
| US-5846998-A | Use of phosphotyrosine phosphatase inhibitors or phosphotyrosine kinase activators for controlling cellular proliferation | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-12-08 | — | — | US | disclosed |
| US-5693627-A | TREATING DISEASES SUCH AS LEUKEMIAS AND LYMPHOMAS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-12-02 | — | — | US | disclosed |
| US-5583242-A | VANADYL COMPLEXES | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-12-10 | — | — | US | disclosed |
| US-5565491-A | FOR TREATMENT OF DISEASES MARKED BY MALIGNANT PROLIFERATION OF B CELLS, SUCH AS LEUKEMIA AND LYMPHOMAS; ANTICARCINOGENIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-10-15 | — | — | US | disclosed |
| WO-1995020390-A1 | USE OF VANADIUM MOLYBDENUM OR TUNGSTEN COMPLEXES FOR CONTROLLING CELLULAR PROLIFERATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250269043-A1 | TARGETED BIFUNCTIONAL DEGRADERS | SMURF2, SMURF1, MDM2 | HPGD 4489/4885ALOX15 4328/4885HSD17B10 4149/4885 |
| US-20230087994-A1 | TARGETED BIFUNCTIONAL DEGRADERS | SMURF2, SMURF1, SSB | HPGD 4608/4885ALOX15 4388/4885HSD17B10 4132/4885 |
| US-20080306031-A1 | Methods of Inhibiting Poxvirus Growth | TTK, TXK, DCK | HPGD 2912/4885ALOX15 3963/4885HSD17B10 2899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.